Swiss National Bank - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 86 filers reported holding REVANCE THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 1.69 and the average weighting 1.4%.

Quarter-by-quarter ownership
Swiss National Bank ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$500,251
-47.8%
194,6500.0%0.00%
-100.0%
Q1 2024$957,678
-33.8%
194,650
+18.2%
0.00%0.0%
Q4 2023$1,447,274
-31.7%
164,650
-10.9%
0.00%
-50.0%
Q3 2023$2,119,082
-54.1%
184,750
+1.2%
0.00%
-33.3%
Q2 2023$4,620,341
-19.2%
182,550
+2.8%
0.00%
-25.0%
Q1 2023$5,718,886
+58.2%
177,550
-9.3%
0.00%
+33.3%
Q4 2022$3,615,391
-30.1%
195,850
+2.2%
0.00%
-25.0%
Q3 2022$5,172,000
+132.1%
191,550
+18.8%
0.00%
+100.0%
Q2 2022$2,228,000
-29.1%
161,2500.0%0.00%0.0%
Q1 2022$3,144,000
+28.9%
161,250
+7.9%
0.00%
+100.0%
Q4 2021$2,439,000
-41.4%
149,4500.0%0.00%
-66.7%
Q3 2021$4,164,000
-6.0%
149,4500.0%0.00%0.0%
Q2 2021$4,430,000
+15.9%
149,450
+9.3%
0.00%0.0%
Q1 2021$3,822,000
+0.5%
136,750
+1.9%
0.00%0.0%
Q4 2020$3,802,000
+30.0%
134,150
+15.3%
0.00%
+50.0%
Q3 2020$2,925,000
+4.7%
116,350
+1.7%
0.00%0.0%
Q2 2020$2,795,000
+109.7%
114,450
+27.1%
0.00%
+100.0%
Q1 2020$1,333,000
-7.7%
90,050
+1.2%
0.00%0.0%
Q4 2019$1,444,000
+51.4%
88,950
+21.3%
0.00%0.0%
Q3 2019$954,000
+0.3%
73,3500.0%0.00%0.0%
Q2 2019$951,000
-13.2%
73,350
+5.6%
0.00%0.0%
Q1 2019$1,095,000
+4.1%
69,450
+32.9%
0.00%0.0%
Q4 2018$1,052,000
-17.1%
52,250
+2.4%
0.00%0.0%
Q3 2018$1,269,000
-9.4%
51,0500.0%0.00%
-50.0%
Q2 2018$1,401,000
-10.9%
51,0500.0%0.00%0.0%
Q1 2018$1,572,000
-14.8%
51,050
-1.2%
0.00%0.0%
Q4 2017$1,846,000
+88.9%
51,650
+45.7%
0.00%
+100.0%
Q3 2017$977,000
+12.7%
35,450
+7.9%
0.00%0.0%
Q2 2017$867,000
+26.9%
32,8500.0%0.00%0.0%
Q1 2017$683,000
+7.2%
32,850
+6.8%
0.00%0.0%
Q4 2016$637,000
+27.9%
30,7500.0%0.00%0.0%
Q3 2016$498,000
+19.1%
30,7500.0%0.00%0.0%
Q2 2016$418,000
-19.3%
30,7500.0%0.00%0.0%
Q1 2016$518,000
-38.7%
30,750
+24.2%
0.00%
-50.0%
Q4 2015$845,000
+36.3%
24,750
+18.7%
0.00%0.0%
Q3 2015$620,000
-0.3%
20,850
+7.2%
0.00%0.0%
Q2 2015$622,000
+132.1%
19,450
+50.2%
0.00%
+100.0%
Q1 2015$268,000
+22.4%
12,9500.0%0.00%0.0%
Q4 2014$219,000
+7.4%
12,950
+22.7%
0.00%0.0%
Q3 2014$204,000
-43.2%
10,5500.0%0.00%0.0%
Q2 2014$359,00010,5500.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q1 2016
NameSharesValueWeighting ↓
NQ HCIF GP, Ltd. 3,096,650$42,114,000100.00%
Essex Woodlands Management, Inc. 4,592,047$62,452,00015.74%
DRILL CRAIG A 65,600$892,0001.76%
UNITED BANK 77,177$1,050,0001.04%
Iguana Healthcare Management, LLC 100,000$1,360,0000.55%
Rhenman & Partners Asset Management AB 220,000$2,992,0000.53%
ArrowMark Colorado Holdings LLC 1,669,992$22,712,0000.46%
Polar Capital LLP 1,168,542$15,891,0000.30%
Vivo Capital, LLC 77,373$1,052,0000.29%
SUFFOLK CAPITAL MANAGEMENT LLC 158,812$2,160,0000.28%
View complete list of REVANCE THERAPEUTICS INC shareholders